In addition to the license agreement, MYR has a collaboration and research agreement with the University Hospital Heidelberg, one of Germany`s most renowned academical centers for biomedical research. Large parts of the non-clinical development and the human Phase 1 trial were performed in Heidelberg. Additional clinical trials with participation of the University Hospital Heidelberg are planed.
MYR has licensed CIS rights for Myrcludex B to Hepatera, who is now conducting the development program with the aim of registration of the drug in CIS countries. The results of the studies will be used as part of the international development effort undertaken by MYR.